A New Approach for Diseases Associated with BH4-Dependent Enzymatic Pathways

Jonathan Reis, President and CEO of Censa Pharmaceuticals, describes the company's novel approach developing therapeutics to treat phenylketonuria and primary BH4 deficiency.

    • Tags:

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Q: